The Structure of (-)-kaitocephalin Bound to the Ligand Binding Domain of the (S)-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA)/glutamate Receptor, GluA2

Overview

Journal J Biol Chem

Specialty Biochemistry

Date 2012 Oct 19

PMID 23076153

Citations 1

Authors

Ahmed H Ahmed

Makoto Hamada

Tetsuro Shinada

Yasufumi Ohfune

Laksiri Weerasinghe

Philip P Garner

Robert E Oswald

Affiliations

Soon will be listed here.

Abstract

Glutamate receptors mediate the majority of excitatory synaptic transmission in the central nervous system, and excessive stimulation of these receptors is involved in a variety of neurological disorders and neuronal damage from stroke. The development of new subtype-specific antagonists would be of considerable therapeutic interest. Natural products can provide important new lead compounds for drug discovery. The only natural product known to inhibit glutamate receptors competitively is (-)-kaitocephalin, which was isolated from the fungus Eupenicillium shearii and found to protect CNS neurons from excitotoxicity. Previous work has shown that it is a potent antagonist of some subtypes of glutamate receptors (AMPA and NMDA, but not kainate). The structure of kaitocephalin bound to the ligand binding domain of the AMPA receptor subtype, GluA2, is reported here. The structure suggests how kaitocephalin can be used as a scaffold to develop more selective and high affinity antagonists for glutamate receptors.

Citing Articles

Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms.

Anjum A, Yazid M, Daud M, Idris J, Ng A, Naicker A Int J Mol Sci. 2020; 21(20).

PMID: 33066029 PMC: 7589539. DOI: 10.3390/ijms21207533.

References

Taverna F, Xiong Z, Brandes L, Roder J, Salter M, MacDonald J . The Lurcher mutation of an alpha-amino-3-hydroxy-5-methyl- 4-isoxazolepropionic acid receptor subunit enhances potency of glutamate and converts an antagonist to an agonist. J Biol Chem. 2000; 275(12):8475-9. DOI: 10.1074/jbc.275.12.8475. View

Liu S, Zukin R . Ca2+-permeable AMPA receptors in synaptic plasticity and neuronal death. Trends Neurosci. 2007; 30(3):126-34. DOI: 10.1016/j.tins.2007.01.006. View

Derkach V, Oh M, Guire E, Soderling T . Regulatory mechanisms of AMPA receptors in synaptic plasticity. Nat Rev Neurosci. 2007; 8(2):101-13. DOI: 10.1038/nrn2055. View

Heath P, Shaw P . Update on the glutamatergic neurotransmitter system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve. 2002; 26(4):438-58. DOI: 10.1002/mus.10186. View

Ahmed A, Wang S, Chuang H, Oswald R . Mechanism of AMPA receptor activation by partial agonists: disulfide trapping of closed lobe conformations. J Biol Chem. 2011; 286(40):35257-66. PMC: 3186401. DOI: 10.1074/jbc.M111.269001. View

Otwinowski Z, Minor W . Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997; 276:307-26. DOI: 10.1016/S0076-6879(97)76066-X. View

Hynd M, Scott H, Dodd P . Glutamate-mediated excitotoxicity and neurodegeneration in Alzheimer's disease. Neurochem Int. 2004; 45(5):583-95. DOI: 10.1016/j.neuint.2004.03.007. View

Kasper C, Pickering D, Mirza O, Olsen L, Kristensen A, Greenwood J . The structure of a mixed GluR2 ligand-binding core dimer in complex with (S)-glutamate and the antagonist (S)-NS1209. J Mol Biol. 2006; 357(4):1184-201. DOI: 10.1016/j.jmb.2006.01.024. View

Furukawa H, Gouaux E . Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core. EMBO J. 2003; 22(12):2873-85. PMC: 162155. DOI: 10.1093/emboj/cdg303. View

10.

Wo Z, Oswald R . Unraveling the modular design of glutamate-gated ion channels. Trends Neurosci. 1995; 18(4):161-8. DOI: 10.1016/0166-2236(95)93895-5. View

11.

Takahashi K, Yamaguchi D, Ishihara J, Hatakeyama S . Total synthesis of (-)-kaitocephalin based on a Rh-catalyzed C-H amination. Org Lett. 2012; 14(6):1644-7. DOI: 10.1021/ol300431n. View

12.

Lau C, Zukin R . NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders. Nat Rev Neurosci. 2007; 8(6):413-26. DOI: 10.1038/nrn2153. View

13.

Limon A, Reyes-Ruiz J, Vaswani R, Chamberlin A, Miledi R . Kaitocephalin antagonism of glutamate receptors expressed in Xenopus oocytes. ACS Chem Neurosci. 2010; 1(3):175-181. PMC: 2860192. DOI: 10.1021/cn900037c. View

14.

Kawasaki M, Shinada T, Hamada M, Ohfune Y . Total synthesis of (-)-kaitocephalin. Org Lett. 2005; 7(19):4165-7. DOI: 10.1021/ol0515154. View

15.

Ahmed A, Wang Q, Sondermann H, Oswald R . Structure of the S1S2 glutamate binding domain of GLuR3. Proteins. 2008; 75(3):628-37. PMC: 2732992. DOI: 10.1002/prot.22274. View

16.

Gill A, Birdsey-Benson A, Jones B, Henderson L, Madden D . Correlating AMPA receptor activation and cleft closure across subunits: crystal structures of the GluR4 ligand-binding domain in complex with full and partial agonists. Biochemistry. 2008; 47(52):13831-41. PMC: 2629381. DOI: 10.1021/bi8013196. View

17.

Cokic B, Stein V . Stargazin modulates AMPA receptor antagonism. Neuropharmacology. 2008; 54(7):1062-70. DOI: 10.1016/j.neuropharm.2008.02.012. View

18.

Jin R, Singh S, Gu S, Furukawa H, Sobolevsky A, Zhou J . Crystal structure and association behaviour of the GluR2 amino-terminal domain. EMBO J. 2009; 28(12):1812-23. PMC: 2699365. DOI: 10.1038/emboj.2009.140. View

19.

Ahmed A, Thompson M, Fenwick M, Romero B, Loh A, Jane D . Mechanisms of antagonism of the GluR2 AMPA receptor: structure and dynamics of the complex of two willardiine antagonists with the glutamate binding domain. Biochemistry. 2009; 48(18):3894-903. PMC: 2693247. DOI: 10.1021/bi900107m. View

20.

Newman D, Cragg G . Natural products as sources of new drugs over the 30 years from 1981 to 2010. J Nat Prod. 2012; 75(3):311-35. PMC: 3721181. DOI: 10.1021/np200906s. View